Radiation cystitis
Also known as: Radiation-induced cystitis, Radiation-induced bladder injury, Radiation-associated cystitis, Radiation haemorrhagic cystitis
Radiation cystitis denotes bladder injury secondary to pelvic radiotherapy, manifesting clinically as urinary frequency, urgency, dysuria, or haematuria. Chronic inflammation may progress to fibrosis. Differential diagnoses must include urinary tract infection, obstruction, and recurrent malignancy; symptoms should not be attributed to radiation sequelae without adequate clinical exclusion. Traditional Chinese Medicine is utilised as adjunctive therapy and must not delay oncological or urological interventions. The cited evidence includes no clinical acupuncture trials and fails to establish the efficacy of the listed formulas. Although a small meta-analysis observed a reduced incidence of cystitis when *Brucea javanica* oil emulsion was administered during cervical cancer treatment, the evidence was of low to very low certainty and does not confirm benefit for established cystitis. Nanozyme and Icariside II data remain restricted to preclinical models, and evidence for platelet-rich plasma is confined to a single case report.
Plain-English one-pager you can print or hand to a patient. Free, no sign-in needed.
Lifestyle & Diet
- •Maintain a voiding diary recording frequency, nocturia, pain, incontinence, and haematuria for clinical review.
- •Distribute fluid intake evenly throughout the day in accordance with medical advice, adhering to any specific cardiac or renal fluid restrictions.
- •Moderately reduce intake of caffeine, alcohol, or acidic beverages only if they are identified as symptom triggers; avoid unnecessarily restrictive dietary measures.
- •Balance gentle physical activity with scheduled rest periods and maintain strict adherence to all oncological and urological follow-up appointments.
Cautions & Contraindications
- •Defer acupuncture and herbal treatment during acute retention, significant haematuria or suspected systemic infection pending medical assessment. Record 3 provides retention context, not evidence for acupuncture safety thresholds.[]
- •Do not substitute these formulas, Brucea products or experimental interventions for oncology or urology care. The low-certainty Brucea findings cannot be extrapolated to the listed formulas; nanozyme and Icariside II studies do not establish human safety or benefit.[,,]
- •During chemoradiotherapy, obtain the treating team's advice regarding blood counts, anticoagulation and herbal interactions. Defer invasive adjunctive procedures with clinically significant thrombocytopenia or neutropenia according to local oncology policy. This is a general precaution, not a protocol evaluated in record 1.[]
When to reassess or seek care again
Review after 1–2 weeks, or sooner if symptoms worsen, using a three-day bladder diary, nocturia count, pain score out of 10 and reported bleeding. Do not continue adjunctive treatment without review if there is no meaningful improvement after 2–4 weeks. New haematuria, worsening emptying or escalating pain requires medical reassessment; acute retention or heavy bleeding requires emergency care. Safety recommendations here are general clinical precautions: the supplied abstracts do not provide comprehensive triage, needling or herb-interaction guidance.
Explore more diseases
Sources & Further Reading
Clinical guidance, red flags and safety notes on this page draw on the following current sources alongside the classical references above.
- Oncology reviews · 2026
- Journal of nanobiotechnology · 2026
- Potential Effect of Intravesical Platelet-Rich Plasma Injection on Urinary Retention: A Case Report.Clinical case reports · 2025
- International journal of surgery (London, England) · 2026
Educational reference for licensed practitioners. Not a substitute for individual clinical assessment. Refer to conventional care for any red-flag or undiagnosed presentation.
